| Clive A. Meanwell |
Clive A. Meanwell founded The Medicines Co. in 1996, where he worked as Chief Innovation Officer & Director in 2020, Population Health Partners LLC in 2020, where he is working as Chairman & Managing Partner from 2020, Population Health Investment Co., Inc. in 2020, where he is working as Chief Executive Officer & Director from 2020, and Metsera, Inc. in 2022, where he is working as Chief Executive Officer & Director from 2022. Dr. Meanwell also currently works at Annovation BioPharma, Inc., as Chief Executive Officer & Director, BB Biotech AG, as Vice Chairman from 2011, Saama Technologies, Inc., as Director from 2021, Pharmaceutical Research & Manufacturers of America, as Director, Fractyl Health, Inc., as Independent Director from 2021, Hugo Health, Inc., as Director, Invivyd, Inc., as Director from 2022, Comanche Biopharma Corp., as Director, and Biotechnology Innovation Organization, as Member. Dr. Meanwell also formerly worked at Rempex Pharmaceuticals, Inc., as Chief Executive Officer, Roche Holding AG, as Director & Senior Vice President from 1987 to 1996, Endo Health Solutions, Inc., as Director from 2005 to 2010, MPM BioImpact, Inc, as Managing Director & Partner from 1995 to 1996, EQRx, Inc., as Independent Director from 2020 to 2023, Targanta Therapeutics Corp., as President, and Hoffmann-La Roche, Inc., as Senior Vice President from 1992 to 1995. Dr. Meanwell received his doctorate degree from the University of Birmingham. |
| Mark Timney |
Mark Timney is the founder of Anfield Road LLC, which was founded in 2017. He is currently the Chief Executive Officer & Director at Attralus, Inc. and Chairman at Blade Therapeutics, Inc. He is also a Director at Biotechnology Innovation Organization and Pharmaceutical Research & Manufacturers of America. Additionally, he is an Independent Director at Sarissa Capital Acquisition Corp. Mr. Timney's former positions include Chief Executive Officer & Director at The Medicines Co. from 2018 to 2020, President & Chief Executive Officer at Purdue Pharma LP from 2014 to 2017, and President-Global Primary Care at Merck & Co., Inc. from 1999 to 2014. Mr. Timney received his undergraduate degree from the University of Northumbria in 1986. |
| Diane E. Sullivan |
Diane E. Sullivan currently works at Amarin Corp. Plc, as Independent Director from 2023 and Lexicon Pharmaceuticals, Inc., as Director from 2023. Ms. Sullivan also formerly worked at OrthogenRx, Inc., as Director from 2018 to 2022, National Association of Specialty Pharmacy, as Director, Pfizer Inc., as VP-Specialty Care Payer & Channel Group from 2009 to 2013, The Medicines Co., as Chief Commercial Officer from 2018 to 2020, and Dalcor Pharmaceuticals US LLC, as Chief Commercial Officer from 2020 to 2021. Ms. Sullivan received her undergraduate degree from Dickinson College. |
| Alexander John Denner |
Alexander John Denner is the founder of Sarissa Capital Management LP, which was founded in 2012. He currently holds the position of Chief Executive Officer & Chief Investment Officer at Sarissa Capital Management LP. Dr. Denner also holds current positions as an Independent Director at Ironwood Pharmaceuticals, Inc. since 2020, an Independent Director at Attralus, Inc. since 2021, and a Member-Supervisory Board at Biogen GmbH since 2009. In his former roles, Dr. Denner served as the Chairman & Chief Executive Officer of Sarissa Capital Acquisition Corp. from 2020 to 2022, the Non-Executive Chairman of Enzon Pharmaceuticals, Inc. from 2009 to 2013, the Chairman of ARIAD Pharmaceuticals, Inc. in 2016 and 2017, the Chairman of The Medicines Co. from 2018 to 2020, an Independent Director of Amylin Pharmaceuticals, Inc. from 2009 to 2012, a Director at Forest Laboratories, Inc., a Director at ImClone LLC from 2006 to 2008, an Independent Director of Biogen, Inc. from 2009 to 2023, an Independent Director of VIVUS, Inc. from 2013 to 2015, a Director of Mast Therapeutics, Inc. from 2006 to 2009, a Director at Genzyme Corp., an Executive Director at Morgan Stanley Investment Management, Inc. from 2001 to 2005, a Senior Managing Director at Icahn Partners LP from 2006 to 2011, a Managing Director at Icahn Partners Master Fund LP, a Senior Managing Director at Icahn Capital LP from 2006 to 2011, a Director at Biogen Idec New Ventures, Inc., a Director at HyperMed, Inc., a Director at Bioverativ, Inc. in 2017 and 2018, and a Portfolio Manager at Viking Global Investors LP in 2005. Dr. Denner's education includes an undergraduate degree from Massachusetts Institute of Technology and graduate and doctorate degrees from Yale University. |
| Stephen M. Rodin |
Stephen M. Rodin is currently the Secretary & Director at Annovation BioPharma, Inc., as well as the Executive Vice President & General Counsel at The Medicines Co. He will also be serving as the Secretary, Senior VP & General Counsel at Aadi Bioscience, Inc. starting in 2022. Previously, he worked as an Associate at Proskauer Rose LLP from 2002 to 2007. Rodin received his undergraduate degree from Georgetown University in 1997 and his graduate degree from Vanderbilt Law School in 2002. |
| John C. Kelly |
John C. Kelly is currently a Director at The Medicines Co. He previously worked as an Independent Director at C. R. Bard, Inc. from 2011 to 2017. He also held positions as a Director at Horizon Healthcare Services, Inc., Vice President & Controller at Wyeth LLC from 2008 to 2009, and Senior Vice President-Finance at Pfizer Inc. from 2009 to 2010. Prior to that, he was a Partner-Audit & Business Consulting Practices at Arthur Andersen LLP and a Council Member at The American Institute of Certified Public Accountants. He also served as a Trustee at The Seeing Eye, Inc. Mr. Kelly received his undergraduate and MBA degrees from Seton Hall University. |
| Geno J. Germano |
Geno J. Germano is currently the President, Chief Executive Officer & Director at Elucida Oncology, Inc., Chairman at SAGE Therapeutics, Inc., Independent Director at Precision BioSciences, Inc., and a Member of the Group of 50. He previously held positions as a Director at The Medicines Co., Director at Biotechnology Innovation Organization, Director at Zoetis, Inc., Managing Director at Wyeth Australia Pty Ltd. and Wyeth New Zealand, Independent Director at Bioverativ, Inc., President & General Manager-Specialty Care at Wyeth LLC, Group President-Global Innovative Pharma Business at Pfizer Inc., President at Precigen, Inc., and Trustee at Albany College of Pharmacy & Health Sciences. Mr. Germano obtained his undergraduate degree from Albany College of Pharmacy & Health Sciences in 1983. |
